LSD / psilocybin / psilocin and MDMA

https://dxm-atlas.org/en/compare/lsd-vs-mdma/

Two separate pairs are shown: DXM + A and DXM + B. Assessing DXM + A + B falls outside the scope of this comparison.

Comparison sections

Overlapping ranges: the ordering by hazard level remains uncertain

PHI and scope

A

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

Conditions and group scope

A

LSD, psilocybin, psilocin

B

MDMA

Mechanisms

A

5HT-R — Serotonin receptors

B

REL — Monoamine release · 2D6 — CYP2D6 metabolism · SYM — Cardiovascular and thermal stress

What could go wrong?

A

Direct organ toxicity of the interaction not established; vomiting and autonomic effects possible [1, 8]

B

Serotonergic and autonomic stress; marked alteration of DXM PK; *High D concerns PK [3]

How well is this understood?

A

Mechanism confidence: medium

Confidence in the mechanism: medium

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
differs
Confidence in human DXM data: low

Confidence in direct human evidence involving DXM: low

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
differs
Flags differ

B

Mechanism confidence: high

Confidence in the mechanism: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
differs
Confidence in human DXM data: high

Confidence in direct human evidence involving DXM: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
differs

Measurements of drug concentration or metabolism.

Flags differ

Under which conditions was it studied?

A

—

B

Measurements of how people process a substance

Main limitations

This field lists specific limitations of the evidence described for each entry. “—” means no separate text is shown here; qualifications in the entry’s explanation still apply.

A

—

B

The measurements concern DXM and its metabolites. The fold increase depends on exposure and can differ at other doses. The abstract reports CYP2D6 recovery after approximately 10 days. The full text estimates a recovery half-life of 46.6 hours from a monoexponential fit to a urinary metabolic-ratio marker and describes a remaining departure from baseline at the 10-day observation [3]. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval. The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3]. The study did not determine the duration of MDMA intoxication or a safe waiting interval for an individual [3].

Sources

Similarities and differences

Effects involved

Only A: 5HT-R — Serotonin receptors

Only B: REL — Monoamine release · 2D6 — CYP2D6 metabolism · SYM — Cardiovascular and thermal stress

Mechanism groups

Shared: Serotonin-related

Only B: Cardiovascular and thermal · Metabolism

Study conditions

Only B: Measurements of how people process a substance

No shared tags are marked in the review.

Conclusion

With psychological effects given relatively little weight, LSD and psilocybin rank below MDMA and MAOIs. These groups differ in the serotonin-elevating mechanisms underlying the assessment [8].

Limitations

A controlled study involved 15 healthy men. They took MDMA by mouth, followed by DXM as a metabolic probe. DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3].

The abstract reports CYP2D6 recovery after approximately 10 days and a recovery half-life of 46.6 hours. The full text estimates that half-life by fitting a monoexponential model to a urinary metabolic-ratio marker. At the 10-day observation, the Results and Discussion describe a remaining departure of the marker from baseline and limitations of the recovery models [3].

These findings describe pharmacokinetics and enzyme-probe measurements. The fold change can differ at other doses because of metabolic saturation and exposure-dependent inhibition. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval.

The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].

Learn
Select entry
Reference

Open the source and related combinations →